Ayahuasca’s Role in the Entourage Effect and Depression

Research suggests that DMT may not be the only compound responsible for ayahuasca's effects.


Ayahuasca Brew and the Psychedelic Renaissance 

Ayahuasca is a traditional psychoactive preparation from mystical-religious rituals, used for centuries for spiritual and healing purposes by more than 70 indigenous groups in the Amazon basin region in South America.1 Since 1930, its use has been incorporated by other religions, and, ever since, the tradition began to reach urban centers.

Today, ayahuasca is part of non-indigenous syncretistic practices. It has spread around the globe and been incorporated into Western culture. Scientific studies have recently shed light on ayahuasca’s therapeutic properties to treat neuropsychiatric conditions, such as depression and addiction. 

The Cross-Talk Between Ayahuasca Compounds   

It is a major challenge for scientific researchers to bring together the complex mixture of alkaloids present in ayahuasca to the lab bench. The pharmacokinetics of ayahuasca has been widely studied in humans over the years, although different preparations make comparisons between works challenging. However, the most common preparation found is made by decocting Banisteriopsis caapi vines and the leaves of Psychotria viridis, which is ingested orally as an infusion.  

N,N-Dimethyltryptamine (DMT), which is the main psychoactive compound of the infusion, is present in abundance in the leaves of P. viridis, but the perceived effects of ayahuasca depend on the interaction between two compounds.2 This is because DMT is naturally degraded by gastric and hepatic monoaminoxidase A (MAO-A) enzymes. B. caapi contains β-carboline alkaloids such as harmine that act as reversible monoamine oxidase A inhibitors (MAO-AIs), making DMT bioavailable from oral administration and, therefore, able to reach the central nervous system.

Putting aside the activity of β-carbolines as MAO-AIs, the potential antidepressant effects of these substances per se cannot be overlooked. They may have a synergistic action with other compounds present in the ayahuasca brew. This matter raises the question of whether the psychedelic DMT compound is the only protagonist behind the therapeutic effects of ayahuasca, or if they are a result of an “entourage-like” effect of the whole infusion with all its components.

Do β-Carboline Alkaloids Play a Role in the Antidepressant Effect?

The truth is that despite not being a classic psychedelic, some studies have shown that harmine alone elicits antidepressant effects and MAO-A inhibition is believed to be the mechanism by which this occurs.3 It is noteworthy that selectivity for MAO-A inhibition and reversibility makes harmine even safer than traditional nonselective, irreversible MAOIs prescribed as antidepressants. 

Moreover, harmine can trigger neurogenesis in neural progenitor cells, and animals treated with harmine had increased levels of brain-derived neurotrophic factor (BDNF), which could underlie its putative antidepressant properties.3,4  Therefore, it is reasonable to assume that although a robust body of science is now depicting DMT’s positive effects on mood with great potential as an antidepressant or anxiolytic, 5,6 accumulating evidence through the years indicates that harmine may also be beneficial for brain health. 

Harmines in ayahuasca may have antidepressant properties.

Lucas Borba / Shutterstock

There are few clinical data on the psychological and psychiatric effects on humans for other compounds isolated from ayahuasca. On the other hand, there is growing interest in whole ayahuasca, which has been demonstrated to have remarkable safety and tolerability.7,8 The first randomized placebo-controlled trial to assess antidepressant effects of ayahuasca, reported significant remission of depressive symptoms after a single dose in treatment-resistant individuals.9 Moreover, long-term ayahuasca users have shown reduced ratings of suffering.10,11

Interestingly, different preparations of ayahuasca with distinct perceived effects present greater concentration variability of ß-carboline alkaloids than DMT itself.12 Preclinical evidence, especially from in vitro studies, suggests that the three main alkaloids present in ayahuasca have great potential to promote neural plasticity by themselves, which could result in the amelioration of depressive symptoms.3 Scientists are only beginning to understand the compounds in ayahuasca along with their chemistry and pharmacology. Therefore, no one can state at this time that DMT alone is responsible for ayahuasca’s perceived positive effects and potential therapeutic applications.

The pharmacological interaction between DMT and MAO inhibitors is probably beyond simply making DMT psychoactive when ingested orally.13 In fact, it was reported by McKenna et al. in 1984 that the combined effects of ß-carbolines are additive, which means they may not interact directly, but their combination is the sum of the effect of each compound given alone.14  Also, ayahuasca brew consumption increases the amount of serotonin (5-HT) in synaptic clefts, which suggests that a serotonin reuptake inhibition mechanism is at work, probably produced by the additive effects of other molecules besides DMT, such as β-carbolines.15

Concluding Remarks 

Psychedelic science can learn a lot from medical Cannabis research. It is now clear that the therapeutic benefits of Cannabis are unlikely due to a single molecule but probably attributed to the molecular interaction in whole-plant extracts, which are more efficacious than their isolated components.16 

The possibility of an entourage effect is gaining support also for psychedelic-containing plants and fungi and could be a lesson to think about when it comes to natural preparations of ayahuasca as a medicine. The great potential of ayahuasca to manage depression could be a catharsis for patients which is borne from B. caapi and P. viridis as they occur in nature. 

José is a biomedical scientist, specialist in Neurorehabilitation, master in Cell Biology, and Assistant Professor of Tissue Biology based in Brazil. He is currently pursuing his PhD in Cellular Biology, investigating the effects of psychedelics on brain organoids at the Federal University of Rio de Janeiro (UFRJ).


Notify of

1 Comment
Newest Most Voted
Inline Feedbacks
View all comments
Sean Merrick
3 years ago

Mother Aya, as the Shipibo-Conibo lineage has known for centuries, is a master nurturer who fosters self-authenticity beyond Western, egoic mindsets. That said, I am struggling with the industrialization of her wisdom. Mother Aya does not need to be peer-reviewed or researched. She needs to be found, drank and honored!

  1. Estrella-Parra EA, Almanza-Pérez JC, Alarcón-Aguilar FJ. Ayahuasca: Uses, Phytochemical and Biological Activities. Nat Products Bioprospect. 2019;9(4):251-265. doi:10.1007/s13659-019-0210-5
  2. Carbonaro TM, Gatch MB. Neuropharmacology of N,N-dimethyltryptamine. Brain Res Bull. 2016;126(Pt 1):74-88. doi:10.1016/j.brainresbull.2016.04.016
  3. Morales-García JA, De La Fuente Revenga M, Alonso-Gil S, et al. The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Sci Rep. 2017;7(1). doi:10.1038/s41598-017-05407-9
  4. Dakic V, Maciel R de M, Drummond H, Nascimento JM, Trindade P, Rehen SK. Harmine stimulates proliferation of human neural progenitors. PeerJ. 2016;4:e2727. doi:10.7717/peerj.2727
  5. Cameron LP, Benson CJ, Defelice BC, Fiehn O, Olson DE. Chronic, Intermittent Microdoses of the Psychedelic N, N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents. ACS Chem Neurosci. 2019;10(7):3261-3270. doi:10.1021/acschemneuro.8b00692
  6. Cameron LP, Benson CJ, Dunlap LE, Olson DE. Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression. ACS Chem Neurosci. 2018;9(7):1582-1590. doi:10.1021/acschemneuro.8b00134
  7. Riba J, Rodríguez-Fornells A, Urbano G, et al. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berl). 2001;154(1):85-95. doi:10.1007/s002130000606
  8. dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JEC. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Rev Clin Pharmacol. 2018;11(9):889-902. doi:10.1080/17512433.2018.1511424
  9. Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychol Med. 2019;49(4):655-663. doi:10.1017/S0033291718001356
  10. Jiménez-Garrido DF, Gómez-Sousa M, Ona G, et al. Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combination. Sci Rep. 2020;10(1):1-12. doi:10.1038/s41598-020-61169-x
  11. Grob CS, McKenna DJ, Callaway JC, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis. 1996;184(2):86-94. doi:10.1097/00005053-199602000-00004
  12. Kaasik H, Souza RCZ, Zandonadi FS, Tófoli LF, Sussulini A. Chemical Composition of Traditional and Analog Ayahuasca. J Psychoactive Drugs. 2020. doi:10.1080/02791072.2020.1815911
  13. Ruffell S, Netzband N, Bird C, Young AH, Juruena MF. The pharmacological interaction of compounds in ayahuasca: a systematic review. Brazilian J Psychiatry. 2020;(AHEAD). doi:10.1590/1516-4446-2020-0884
  14. McKenna DJ, Towers GHN, Abbott F. Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β-carboline constituents of Ayahuasca. J Ethnopharmacol. 1984;10(2):195-223. doi:10.1016/0378-8741(84)90003-5
  15. Callaway JC, Airaksinen MM, McKenna DJ, Brito GS, Grob CS. Platelet serotonin uptake sites increased in drinkers of ayahuasca. Psychopharmacology (Berl). 1994;116(3):385-387. doi:10.1007/BF02245347
  16. Russo EB. The case for the entourage effect and conventional breeding of clinical cannabis: No “Strain,” no gain. Front Plant Sci. 2019;9. doi:10.3389/fpls.2018.01969